Release Date:
December 03, 2013 (All day)
For immediate release
Minneapolis, MN - December 03, 2013 - ImmunoChemistry Technologies (ICT), a Minnesota-based biotechnology company that supplies unique biochemical laboratory reagents and assay tests to medical researchers, has changed ownership. Now majority women-owned, ICT develops new products to help researchers discover new treatments and drugs for cancer and other diseases affecting both animals and humans.
The privately held company is now majority owned by Sally Hed, VP of Marketing and Operations, and Carol Lee, secretary and board member. Dr. Brian W. Lee, Ph.D., president and co-founder, owns one-third of the company and is in charge of ICT’s research and development. ICT has consistently achieved double-digit growth thanks to a solid customer base with an international distributor network serving labs all over the world.
December 03, 2013 (All day)
For immediate release
ImmunoChemistry Technologies Changes Ownership
Biomedical laboratory developing proprietary and patented reagents for cancer research is now majority women-owned.
 |
| Sally Hed, ImmunoChemistry Technologies VP of Marketing and Operations |
The privately held company is now majority owned by Sally Hed, VP of Marketing and Operations, and Carol Lee, secretary and board member. Dr. Brian W. Lee, Ph.D., president and co-founder, owns one-third of the company and is in charge of ICT’s research and development. ICT has consistently achieved double-digit growth thanks to a solid customer base with an international distributor network serving labs all over the world.
"Someday, doctors will be able to tell if the treatment is working within a matter of hours because they’ll be able to see on a molecular level how many cancer cells are dying in response to treatment," said Sally Hed, VP of Marketing and Operations.
